New combo therapy shows promise for advanced nose cancer
NCT ID NCT03734809
First seen Jan 05, 2026 · Last updated May 08, 2026 · Updated 21 times
Summary
This study tested a new treatment for people with stage IVA nasopharyngeal cancer, a type of nose and throat cancer. The treatment combined the immunotherapy drug pembrolizumab with chemotherapy and radiation, followed by maintenance pembrolizumab for a year. The goal was to see if this approach could keep the cancer from growing for at least two years. The study enrolled 43 adults and is no longer recruiting new participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NPC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Clinical Oncology, Prince of Wales Hospital
Hong Kong, Hong Kong
-
National Cancer Centre of Singapore
Singapore, Singapore
Conditions
Explore the condition pages connected to this study.